Media stories about NuVasive (NASDAQ:NUVA) have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NuVasive earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 46.6260082554167 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

A number of research analysts have recently issued reports on NUVA shares. Jefferies Group LLC restated a “buy” rating and issued a $79.00 price target on shares of NuVasive in a research report on Sunday, July 30th. Canaccord Genuity restated a “buy” rating and issued a $80.00 price target on shares of NuVasive in a research report on Friday, July 28th. Barclays PLC restated a “buy” rating and issued a $80.00 price target on shares of NuVasive in a research report on Wednesday, August 2nd. Gabelli restated a “buy” rating on shares of NuVasive in a research report on Monday, July 31st. Finally, Royal Bank Of Canada reiterated a “buy” rating and set a $85.00 target price on shares of NuVasive in a research report on Thursday, July 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $72.33.

Shares of NuVasive (NASDAQ NUVA) opened at $55.70 on Thursday. The company has a market cap of $2,879.18, a price-to-earnings ratio of 29.89, a price-to-earnings-growth ratio of 2.01 and a beta of 0.78. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.51 and a current ratio of 2.85. NuVasive has a one year low of $49.25 and a one year high of $81.68.

NuVasive (NASDAQ:NUVA) last announced its quarterly earnings results on Tuesday, October 24th. The medical device company reported $0.52 EPS for the quarter, beating the Zacks’ consensus estimate of $0.48 by $0.04. The business had revenue of $247.40 million during the quarter, compared to analyst estimates of $255.70 million. NuVasive had a net margin of 6.36% and a return on equity of 13.65%. NuVasive’s quarterly revenue was up 3.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.40 EPS. equities research analysts forecast that NuVasive will post 1.91 earnings per share for the current fiscal year.

NuVasive announced that its board has initiated a stock buyback program on Tuesday, October 24th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the medical device company to buy shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board of directors believes its stock is undervalued.

In other news, CEO Gregory T. Lucier bought 2,000 shares of NuVasive stock in a transaction dated Tuesday, August 29th. The stock was purchased at an average price of $61.52 per share, for a total transaction of $123,040.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Lesley H. Howe sold 3,970 shares of the company’s stock in a transaction on Friday, August 18th. The stock was sold at an average price of $64.64, for a total transaction of $256,620.80. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “NuVasive (NUVA) Earns News Sentiment Score of 0.09” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this story can be accessed at

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Insider Buying and Selling by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with's FREE daily email newsletter.